EpiCast Report: Irritable Bowel Syndrome - Epidemiology Forecast to 2023
Published: Oct-2014 | Format: PDF | GlobalData | Number of pages: 49 | Code: MRS - 2057
Irritable Bowel Syndrome (IBS) is a chronic, relapsing gastrointestinal disorder that is characterized by abdominal discomfort or pain, bloating, and changes in bowel habit. Due to the lack of a demonstrable structural abnormality to explain these symptoms, IBS is classified as a functional gastrointestinal disorder.
IBS is one of the most common gastrointestinal disorders; moreover, it has a significant negative impact on a patient's quality of life and social functioning. That said, IBS is not known to be associated with the development of serious disease or with excess mortality. Several factors, including psychological disorders, stress, environmental factors, infection, and inflammation have been reported to play a role in the pathogenesis of IBS, however, their exact role remains to be clarified.
GlobalData epidemiologists forecast that the total prevalent cases of IBS in the 7MM will increase from 40,777,607 total prevalent cases in 2013 to 42,366,389 by 2023, at a decadal growth rate of 3.9%. Specifically, Spain will have the highest growth in the total prevalent cases of IBS in the 7MM between 2013 and 2023, while Japan and Germany will have a decline in the total prevalent cases of IBS in the 7MM between 2013 and 2023.
GlobalData's epidemiological analysis is supported by the use of epidemiological studies published in peer-reviewed journals and country-specific studies that provided the total prevalence of IBS using the Rome II diagnostic criteria. GlobalData epidemiologists used uniform methodology across the markets to forecast the total prevalent cases of IBS; GlobalData epidemiologists segmented IBS by sex, age, and subclassification of predominant bowel habits, which allows for a meaningful comparison of the disease populations between markets.
- The Irritable Bowel Syndrome (IBS) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for IBS in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of IBS segmented by sex, age (10-18 years, 19-34 years, 35-44 years, 45-54 years, 55-64 years, 65-74 years, 75-84 years, and =85 years), and subclassification of predominant bowel habits (diarrhea-predominant IBS [IBS-D], constipation-predominant IBS [IBS-C], mixed presentation IBS [IBS-M], and unsubtyped IBS [IBS-U] in these markets.
- The IBS epidemiology report is written and developed by Mastersand PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy
- Develop business strategies by understanding the trends shaping and driving the global IBS market.
- Quantify patient populations in the global IBS market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for IBS therapeutics in each of the markets covered.
Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Introduction 6
2.1 Catalyst 6
2.2 Related Reports 7
2.3 Upcoming Related Reports 7
3 Epidemiology 8
3.1 Disease Background 8
3.2 Risk Factors and Comorbidities 9
3.3 Global Trends 10
3.3.1 US 13
3.3.2 5EU 14
3.3.3 Japan 15
3.4 Forecast Methodology 15
3.4.1 Sources Used 16
3.4.2 Sources Not Used 22
3.4.3 Forecast Assumptions and Methods- Total Prevalent Cases of IBS 23
3.4.4 Forecast Assumptions and Methods - IBS Subtype Segmentations 26
3.5 Epidemiological Forecast forIBS (2013-2023) 28
3.5.1 Total Prevalent Cases of IBS 28
3.5.2 Age-Specific Total Prevalent Cases of IBS 30
3.5.3 Sex-Specific Total Prevalent Cases of IBS 32
3.5.4 Age-Standardized Total Prevalence of IBS 34
3.5.5 Total Prevalent Cases of IBS by Clinical Subtypes 35
3.6 Discussion 37
3.6.1 Epidemiological Forecast Insight 37
3.6.2 Limitations of the Analysis 38
3.6.3 Strengths of the Analysis 40
4 Appendix 41
4.1 Bibliography 41
4.2 About the Authors 45
4.2.1 Epidemiologists 45
4.2.2 Reviewers 45
4.2.3 Acting Global Director of Epidemiology 46
4.2.4 Global Head of Healthcare 47
4.3 About GlobalData 47
4.4 About EpiCast 48
4.5 Disclaimer 48
List of Tables
Table 1: Risk Factors and Comorbidities for IBS 10
Table 2: Comparison of the IBS Diagnostic Criteria Used in Epidemiological Studies 12
Table 3: Total Prevalence (%) of IBS in the 7MM, as Reported in Epidemiological Studies 12
Table 4: Total Prevalence (%) of IBS as Reported in Epidemiological Studies in the US 14
Table 5: 7MM, Sources of Total Prevalence Data Used to Forecast the Total Prevalent Cases of IBS 16
Table 6: 7MM, Sources of IBS Subtype Data Used to Forecast the Total Prevalent Cases of IBS by Subtype 17
Table 7: 7MM, Total Prevalent Cases of IBS, Ages ?10 Years, Both Sexes, N, Selected Years 2013-2023 29
Table 8: 7MM, Age-Specific Total Prevalent Cases of IBS, Both Sexes, N (Row %), 2013 31
Table 9: 7MM, Sex-Specific Prevalent Cases of IBS, Ages ?10 Years, N (Row %), 2013 33
Table 10: 7MM Total Prevalent Cases of IBS, N (%), by Clinical Subtypes, Both Sexes, Ages ?10 Years, 2013 36
List of Figures
Figure 1: 7MM, Total Prevalent Cases of IBS Ages ?10 Years, Both Sexes, N, 2013-2023 29
Figure 2: 7MM, Age-Specific Total Prevalent Cases of IBS, Both Sexes, N, 2013 32
Figure 3: 7MM, Sex-Specific Total Prevalent Cases of IBS, Ages ?10 Years, N, 2013 34
Figure 4: 7MM, Age-Standardized Total Prevalence of IBS (%), Ages ?10 Years, by Sex, 2013 35
Figure 5: 7MM Total Prevalent Cases of IBS (%), by Clinical Subtypes, Both Sexes, Ages ?10 Years, 2013 37
Inquiry For Buying
COVID-19 Pandemic Impacts
Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.
Medical QMS Software-United States Market Status and Trend Report 2020-2025
Medical QMS Software-India Market Status and Trend Report 2020-2025
Medical QMS Software-China Market Status and Trend Report 2020-2025
Medical QMS Software-Asia Pacific Market Status and Trend Report 2020-2025
Medical QMS Software-EMEA Market Status and Trend Report 2020-2025View More
Along with 7 Realme Products, Realme Buds Q TWS Earbuds Will Also be Launched on May 25
Realme has added an addition in its product portfolio, i.e., the completely wireless headset Realm
iOS 13.5 and iPaDOS 13.5 Released by Apple Includes Features Relevant with COVID-19
Apple released its iOS 13.5 and iPadOS 13.5 that includes features that are appropriate for post-C
Canada and the US will no Longer Find Talc-based Johnson & Johnson Baby Powder
On Tuesday, Johnson Johnson made an official announcement that talc-based Johnsons Baby Powder wi
Foreign Investments being pulled out from Asian Countries
The world is facing one of deadliest recession of all times and amidst all these the foreign inves
Claims from the British American Tobacco that Coronavirus Vaccine Prepared by them is Ready for Human Trials
Every other region and institutions are trying out their level hard to find vaccination for COVID-